Latest News

Thursday, May 24, 2018

Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosis

Rapamycin lotion significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with tuberous sclerosis complex (TSC), researchers from The University of Texas Health Sci…

Read the full story

Thursday, May 24, 2018

Psoriatic Arthritis Awareness Project Launches

In recognition of Psoriatic Arthritis Action Month, the National Psoriasis Foundation (NPF), in collaboration with Novartis Pharmaceuticals Corporation, has premiered the Psoriatic Arthritis (PsA) Awa…

Read the full story

Wednesday, May 23, 2018

Skincare on Trial: Revision Introduces New Patient-Friendly Option

Revision Skincare has introduced a collection of five comprehensive 45-day trial regimens they say are designed to address the needs of women who depend on professionals for anti-aging …

Read the full story

Wednesday, May 23, 2018

New PSA From American Academy of Dermatology Highlights Dangers of Tanning

As Memorial Day signals the unofficial start of summer, many teen girls will be eager to get out of school and spend time outside -- and some may want to get a tan. But a new public service advertise…

Read the full story

Wednesday, May 23, 2018

Dr. Daniel Siegel Joins MedX’s Medical Advisory Board

Daniel Siegel, MD, Clinical Professor of Dermatology at SUNY Downstate in Brooklyn, New York, and a former President of the American Academy of Dermatology has joined the Medical Advisory Board of Med…

Read the full story

Tuesday, May 22, 2018

FDA Approves Lilly's Taltz for Label Update to Treat Psoriasis Involving the Genital Area

The FDA has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. Eli Lilly and Company's Taltz is the first treatment FDA…

Read the full story

Tuesday, May 22, 2018

EWG: Two-Thirds of Sunscreen Products Offer Poor Protection or Have Worrisome Ingredients

The Environmental Working Group (EWG) released its 12th annual Guide to Sunscreens, rating the safety and efficacy of more than 1,000 sunscreens, moisturizers and lip balms that advertise su…

Read the full story

Monday, May 21, 2018

FDA Greenlights Restylane Lyft for Hand Rejuvenation

The US Food and Drug Administration has approved Restylane Lyft for use on the dorsal hands of people older than 21, making it the first hyaluronic acid (HA) injectable gel approved for this…

Read the full story

Monday, May 21, 2018

Biotin Supplements Caused Misleading Test Results, Almost Led to an Unnecessary Procedure

A new case report in the Journal of the Endocrine Society documents how a patient's use of a biotin supplement, caused her to have clinically misleading test results, which pro…

Read the full story

Monday, May 21, 2018

New Guidelines May Slightly Increase Reliability, Accuracy of Melanoma Diagnoses

New guidelines may slightly increase reliability and accuracy of melanoma diagnoses, a new study in JAMA Network Open shows. The American Joint Committee on Cancer recently updated its guidelines f…

Read the full story

Thursday, May 17, 2018

Glenmark Pharmaceuticals Presents New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at IID Meeting

Glenmark Pharmaceuticals shared data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic …

Read the full story

Thursday, May 17, 2018

ASDS: Skin Cancer Treatment Ranks as Most-Performed Procedure of 2017

The American Society for Dermatologic Surgery (ASDS) members performed nearly 12 million medically necessary and cosmetic procedures in 2017 -- over 10 percent more than 2016 and doubling since 2012…

Read the full story

Thursday, May 17, 2018

Greater Skin Cancer Risk Seen in U.S. Military Personnel

U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD)…

Read the full story

Wednesday, May 16, 2018

FDA Frowns on Evolus’ Botox Rival

The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed …

Read the full story

Wednesday, May 16, 2018

Dupixent Improves Moderate-to-Severe Atopic Dermatitis in Adolescents

DUPIXENT (dupilumab) performed well in a Phase 3 Trial of inadequately controlled moderate-to-severe atopic dermatitis in adolescents, Regeneron and Sanofi report. In the trial, treatment with…

Read the full story
Load More